https://doctransparency.com/doctor/tx/dallas/daniel-gossett-1588980072
Not Medicare Enrolled

Dr. Daniel Gossett, MD

Epilepsy Physician · Dallas, TX
Speaking/Promotional
7920 BELT LINE RD STE 685, Dallas, TX 75254
2145446474
In practice since 2010 (15 years)
NPI: 1588980072 verify on NPPES ↗
Moderate
DATA COVERAGE
Data in 2 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gossett from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gossett? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Gossett

Dr. Daniel Gossett is an epilepsy physician in Dallas, TX, with 15 years in practice.

Between the years covered by Open Payments, Dr. Gossett received a total of $35,605 from 73 pharmaceutical and/or device companies across 797 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in epilepsy physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Gossett is Moderate — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 15 years in practice$ $35,605 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$35,605
Total received (2018-2024)
Avg $5,086/year across 7 years
Top 3% in TX for epilepsy physician
73
Companies
797
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$21,935 (61.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,670 (38.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$14,852
2023
$10,006
2022
$2,349
2021
$3,011
2020
$1,297
2019
$1,830
2018
$2,259

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Marinus Pharmaceuticals, Inc.
$15,902
BioMarin Pharmaceutical Inc.
$5,118
UCB, Inc.
$1,199
Ironshore Pharmaceuticals Inc.
$1,092
Supernus Pharmaceuticals, Inc.
$1,085
NATUS MEDICAL INCORPORATED
$1,012
Sunovion Pharmaceuticals Inc.
$860
LivaNova USA, Inc.
$693
Eisai Inc.
$666
Tris Pharma Inc
$665
Neos Therapeutics, LP
$646
Neurelis, Inc.
$616
SK Life Science, Inc.
$447
JAZZ PHARMACEUTICALS INC.
$442
EISAI INC.
$372
Corium, LLC
$343
AQUESTIVE THERAPEUTICS, INC.
$294
ACADIA Pharmaceuticals Inc
$239
Shire North American Group Inc
$227
Takeda Pharmaceuticals U.S.A., Inc.
$214
Adlon Therapeutics L.P.
$212
Merz Pharmaceuticals, LLC
$202
Lundbeck LLC
$190
Sumitomo Pharma America, Inc.
$187
Zogenix Inc.
$180
ARGENX US, INC.
$171
Biohaven Pharmaceuticals, Inc.
$166
Aprecia Pharmaceuticals, LLC
$160
Ipsen Biopharmaceuticals, Inc
$129
Biogen, Inc.
$126
ABBVIE INC.
$114
ARBOR PHARMACEUTICALS, INC.
$113
Alexion Pharmaceuticals, Inc.
$103
TG Therapeutics, Inc.
$97
Teva Pharmaceuticals USA, Inc.
$93
GENZYME CORPORATION
$68
Validus Pharmaceuticals LLC
$65
Amneal Pharmaceuticals LLC
$60
Allergan, Inc.
$53
Avion Pharmaceuticals
$50
Neurocrine Biosciences, Inc.
$49
NS Pharma, Inc.
$47
Octapharma USA, Inc.
$46
Grifols USA, LLC
$44
PTC Therapeutics, Inc.
$43
PFIZER INC.
$42
Cranial Technologies, Inc
$41
ANI Pharmaceuticals, Inc.
$41
Kedrion Biopharma, Inc.
$40
Travere Therapeutics, Inc.
$36
NEUROPACE, INC.
$33
Biohaven Pharmaceutical Holding Company Ltd.
$32
Sarepta Therapeutics, Inc.
$32
Mallinckrodt Enterprises LLC
$32
Lupin Inc.
$30
Biocodex, Inc.
$30
Aucta Pharmaceuticals, Inc.
$29
Azurity Pharmaceuticals, Inc.
$26
Corium, Inc.
$25
Arbor Pharmaceuticals, Inc.
$24
REVANCE THERAPEUTICS, INC.
$24
Lilly USA, LLC
$21
Noven Therapeutics, LLC
$20
CATALYST PHARMACEUTICALS, INC.
$18
Mallinckrodt LLC
$18
Upsher-Smith Laboratories LLC
$17
Vertical Pharmaceuticals, LLC
$17
Catalyst Pharmaceuticals, Inc.
$15
Mallinckrodt Hospital Products Inc.
$15
HARMONY BIOSCIENCES LLC
$15
GE HEALTHCARE
$14
Retrophin, Inc.
$10
Cycle Pharmaceuticals Inc
$9
Top 3 companies account for 62.4% of total payments
Associated products mentioned in payments ›
(820) Cholbam · ACTHAR · ADHANSIA XR · AMYVID · APTIOM · AZSTARYS · Adzenys XR-ODT · Albuked · Austedo XR · Azstarys · BOTOX · BRIUMVI · Brineura · Briviact · COTEMPLA XR-ODT · Cholbam · Cotempla XR-ODT · DAXXIFY · DAYBUE · DIACOMIT · Doc Band · Dyanavel XR · Dysport · EMFLAZA · EPIDIOLEX · Eprontia · Equetro · Evekeo · Evekeo ODT · Exondys 51 · FYCOMPA · Fintepla · Fycompa · Gamunex-C · HYQVIA · Horizant · INGREZZA · JORNAY PM · Jornay PM 20mg capsules (Bottle of 100) · LUMIZYME · Leqembi · METHYLPHENIDATE 72 · MYDAYIS · Methylphenidate Hydrochloride · Motpoly XR · NUPLAZID · NURTEC ODT · Nayzilam · ONFI · OXTELLAR XR · PANZYGA · POMPE - DISEASE · PURIFIED CORTROPHIN GEL · QELBREE · QUILLIVANT XR · Qelbree · Quillichew ER · Quillivant · Quillivant XR · RNS System · RYTARY · Rystiggo · SKYCLARYS · SOLIRIS · SPINRAZA · SUPRAX · SYMPAZAN · Spritam · TROKENDI XR · Tascenso ODT · ULTOMIRIS · VALTOCO · VIGADRONE (VIGABATRIN) FOR ORAL SOLUTION · VILTEPSO · VNS - Sentiva · VNS THERAPY SENTIVA MODEL 1000 GENERATOR · VNS Therapy · VNS Therapy SenTiva Model 1000 Generator · VYEPTI · VYVANSE · VYVGART HYTRULO · VascuClear · Vimizim · Vimpat · Wakix · XCOPRI · XYREM · Xelstrym · Xeomin · ZOMIG · ZTALMY
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (62%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in epilepsy physician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for epilepsy physician in TX.

Looking for a epilepsy physician in Dallas?
Compare epilepsy physicians in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse epilepsy physicians nearby

Geographic Context

Epilepsy Physicians within 10 mi
8
Per 100K population
0.3
County median income
$74,149
Nearest hospital
MEDICAL CITY GREEN OAKS HOSPITAL
2.2 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment— Not enrolledN/A
Practice Data— No dataN/A
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 2 of 4 available federal datasets, with a Data Coverage level of Moderate. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Gossett is a epilepsy physician, and high industry engagement (speaking/promotional, top 3%), with 15 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Gossett receive payments from pharmaceutical companies?
Yes. Dr. Gossett received a total of $35,605 from 73 companies across 797 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently Moderate for Dr. Gossett) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →